Abstract and Introduction
LARS group) and not attributed to treatment, and the percentages of patients reporting serious adverse events were similar in the ESO group (24.1%) and in the LARS group (28.6%). In conclusion, this multicentre clinical trial demonstrates that, either by drug-induced acid suppression with ESO or by LARS, most patients achieve and remain in symptomatic remission at 5 years.
Commentary
It is essential that this monumental, non-equivalence, non-superiority, exploratory study is dissected carefully, and its findings and conclusions are not misinterpreted or overstated. To this end, several important points need to be considered. First, the participating patients were responders to medical therapy (except for mild symptoms), not partial or complete non-responders. As such, the evidence provided by LOTUS would help the decision about proceeding with the alternative of surgery in those patients who are doing well on PPI but do not wish to take daily PPI with their associated, hitherto theoretical, long-term risks. Hence, these patients and their physicians will have to balance the gains (ie, equal benefits of surgery) with the risks -all nuisance symptoms such as bloating, flatulence and dysphagia -that may happen in the operated patients twice as frequently and may require visits and further interventions. LOTUS's results will not apply to patients with complex, poorly responsive GERD, those with large hiatal hernias and ongoing regurgitation despite PPI or even those patients with heartburn and regurgitation, proven by extensive functional assessment with endoscopy/biopsies, pH monitoring and motility studies to have clear-cut GERD but with grades C or D oesophagitis at baseline. The study would not be applicable to most patients who require ESO 40 mg taken twice daily for symptom control.
Second, this multicentre study was performed in very carefully selected patients who were operated on by expert surgeons at large, academic centres. The results with patients operated on in the community setting or the results among poorly evaluated patients may not be similar, and the success/complication rates of LARS may be inferior to those seen in LOTUS. Numerous studies of long-term outcomes of LARS ranging from 5 to 12 years of follow-up suggest that the percentage of patients experiencing new, recurrent or persistent GERD-related symptoms after primary surgery ranges from 2% to 30%. Between 3% and 10% of these patients with a failed primary surgery undergo a revision, certainly less favourable than that in LOTUS.
What is the take-home message of this study and how do its results fit in with what is currently known in the field? LARS and dose-adjusted ESO are equally effective at 5 years if patients are carefully selected PPI responders and operated on by experts at large centres.
